{
    "organizations": [],
    "uuid": "78feae7bdb5b45bb85349ad4cfb93920ef164959",
    "author": "",
    "url": "https://www.reuters.com/article/brief-adamas-announces-first-patient-enr/brief-adamas-announces-first-patient-enrolled-in-phase-3-trial-of-ads-5102-in-multiple-sclerosis-patients-with-walking-impairment-idUSASC09UQ5",
    "ord_in_thread": 0,
    "title": "BRIEF-Adamas Announces First Patient Enrolled In Phase 3 Trial Of ADS 5102 In Multiple Sclerosis Patients With Walking Impairment",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "Market News April 3, 2018 / 1:17 PM / in 14 minutes BRIEF-Adamas Announces First Patient Enrolled In Phase 3 Trial Of ADS 5102 In Multiple Sclerosis Patients With Walking Impairment Reuters Staff \nApril 3 (Reuters) - Adamas Pharmaceuticals Inc: \n* 5102 IN MULTIPLE SCLEROSIS PATIENTS WITH WALKING IMPAIRMENT Source text for Eikon:  ",
    "published": "2018-04-03T16:16:00.000+03:00",
    "crawled": "2018-04-03T16:39:52.046+03:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "market",
        "news",
        "april",
        "pm",
        "minute",
        "announces",
        "first",
        "patient",
        "enrolled",
        "phase",
        "trial",
        "ad",
        "multiple",
        "sclerosis",
        "patient",
        "walking",
        "impairment",
        "reuters",
        "staff",
        "april",
        "reuters",
        "adamas",
        "pharmaceutical",
        "inc",
        "multiple",
        "sclerosis",
        "patient",
        "walking",
        "impairment",
        "source",
        "text",
        "eikon"
    ]
}